The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...
Scientists have identified a biomarker for Alzheimer's that may help doctors spot the early signs of protein buildup in the ...
Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...
Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...
IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...
T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.
A revolutionary approach to immune therapy has emerged: engineered immune cells that protect healthy tissue without ...
Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...
Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback